MeSH term
Frequency | Condition_Probility | Aged | 13 | 0.0 |
Antimetabolites, Antineoplastic/pharmacology | 2 | 2.0 |
Cytosol/enzymology | 12 | 6.0 |
Female | 33 | 0.0 |
Humans | 109 | 0.0 |
Middle Aged | 17 | 0.0 |
Prognosis | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 82 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Time Factors | 4 | 0.0 |
Animals | 32 | 0.0 |
Cell Cycle/drug effects | 2 | 0.0 |
Comparative Study | 21 | 0.0 |
Mice | 21 | 0.0 |
Thymidine/*metabolism | 3 | 16.0 |
Thymidine Kinase/metabolism | 10 | 33.0 |
Tumor Cells, Cultured | 11 | 0.0 |
Adolescent | 4 | 0.0 |
Adult | 16 | 0.0 |
Breast Neoplasms/*enzymology/pathology | 2 | 6.0 |
Cytosol/*enzymology | 4 | 7.0 |
Immunohistochemistry | 5 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Neoplasm Staging | 5 | 0.0 |
Thymidine Kinase/*analysis | 6 | 85.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Substrate Specificity | 18 | 0.0 |
Thymidine Kinase/*chemistry | 4 | 100.0 |
Cell Cycle | 5 | 0.0 |
Cell Division | 6 | 0.0 |
Cells, Cultured | 10 | 0.0 |
Flow Cytometry | 3 | 0.0 |
G1 Phase | 2 | 0.0 |
G2 Phase | 2 | 1.0 |
Hela Cells | 4 | 0.0 |
Male | 18 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Cell Line | 13 | 0.0 |
Cells, Cultured/radiation effects | 2 | 16.0 |
*Chromosome Aberrations | 2 | 0.0 |
Iron | 2 | 20.0 |
Lymphocytes/radiation effects | 2 | 18.0 |
*Mutation | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 20 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 13 | 0.0 |
Thymidine Kinase/*genetics | 14 | 29.0 |
Anti-HIV Agents/*pharmacology | 4 | 2.0 |
Antiviral Agents/pharmacology | 2 | 3.0 |
Deoxycytidine Kinase/metabolism | 2 | 10.0 |
Child | 7 | 0.0 |
Infant | 2 | 0.0 |
Pregnancy | 3 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
In Vitro | 3 | 0.0 |
Phosphorylation | 18 | 0.0 |
Kinetics | 18 | 0.0 |
Nucleotidases/metabolism | 2 | 25.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Base Sequence | 9 | 0.0 |
DNA Primers | 4 | 0.0 |
Precipitin Tests | 3 | 0.0 |
Protein Binding | 2 | 0.0 |
Thymidine Kinase/*metabolism | 6 | 40.0 |
Species Specificity | 2 | 0.0 |
Models, Biological | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Thymidine Kinase/*immunology | 2 | 100.0 |
Tumor Markers, Biological/*immunology | 2 | 8.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Blotting, Western | 7 | 0.0 |
Alleles | 3 | 0.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 2 | 2.0 |
Thymidine Kinase/genetics | 2 | 2.0 |
Biological Markers/analysis | 3 | 0.0 |
Proliferating Cell Nuclear Antigen/*analysis | 2 | 1.0 |
Reference Values | 4 | 0.0 |
CD4 Lymphocyte Count | 2 | 0.0 |
Adenosine Triphosphate/pharmacology | 2 | 2.0 |
Chromatography, Gel | 3 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Dimerization | 2 | 0.0 |
Enzyme Stability | 2 | 1.0 |
Escherichia coli | 2 | 0.0 |
Lymphocytes/enzymology | 5 | 5.0 |
Amino Acid Substitution | 2 | 0.0 |
Molecular Sequence Data | 13 | 0.0 |
*Protein-Tyrosine Kinase | 2 | 0.0 |
Receptors, Fibroblast Growth Factor/*genetics | 2 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
Isoelectric Focusing | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Thymidine Kinase/*blood | 4 | 50.0 |
Thymine Nucleotides/*metabolism | 2 | 100.0 |
Cell Division/drug effects | 3 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Thymidine Kinase/genetics/*metabolism | 2 | 33.0 |
DNA/metabolism | 3 | 0.0 |
Nucleosides/pharmacology | 2 | 50.0 |
Zalcitabine/metabolism/*pharmacology | 2 | 100.0 |
Deoxycytidine Kinase/antagonists & inhibitors/*metabolism | 2 | 100.0 |
Drug Design | 2 | 0.0 |
Leukemia/*enzymology | 4 | 30.0 |
Structure-Activity Relationship | 4 | 0.0 |
Thymidine Kinase/antagonists & inhibitors/*metabolism | 3 | 100.0 |
Deoxycytidine Kinase/*metabolism | 4 | 11.0 |
Phosphotransferases (Alcohol Group Acceptor)/*metabolism | 3 | 3.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Child, Preschool | 5 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
Osteochondrodysplasias/*genetics | 2 | 2.0 |
Phenotype | 3 | 0.0 |
Apoptosis | 2 | 0.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
*Chromosomes, Human, Pair 17 | 3 | 0.0 |
Gene Library | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 7 | 0.0 |
Models, Genetic | 3 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
*Chromosome Mapping | 6 | 0.0 |
English Abstract | 3 | 0.0 |
*Evolution | 2 | 1.0 |
Genetic Markers | 5 | 0.0 |
Hybrid Cells | 5 | 0.0 |
Chromosome Mapping | 6 | 0.0 |
*Genes, p53 | 2 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Deoxycytidine/metabolism | 3 | 37.0 |
Thymidine/metabolism | 2 | 0.0 |
Leukocytes, Mononuclear/*enzymology | 3 | 12.0 |
Zidovudine/metabolism | 2 | 40.0 |
Molecular Weight | 5 | 0.0 |
Mutation | 4 | 0.0 |
Protein Structure, Quaternary | 2 | 1.0 |
Catalysis | 2 | 0.0 |
*Mitosis | 2 | 1.0 |
Spleen/enzymology | 3 | 9.0 |
Gene Expression Regulation, Enzymologic/drug effects | 2 | 1.0 |
Isoenzymes/metabolism | 3 | 0.0 |
Binding Sites | 5 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Heterozygote | 3 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Chromosomes, Human, Pair 17/*genetics | 2 | 1.0 |
Dideoxynucleosides/*pharmacokinetics | 2 | 100.0 |
Chromosome Banding | 3 | 0.0 |
Hamsters | 3 | 0.0 |
Karyotyping | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Mitochondria/enzymology | 4 | 3.0 |
Thymidine Kinase/isolation & purification/*metabolism | 2 | 100.0 |
Glucosidases/*genetics | 2 | 15.0 |
Adenosine Deaminase/metabolism | 2 | 10.0 |
Adenosine Triphosphate/*metabolism | 3 | 3.0 |
Radioisotope Dilution Technique | 2 | 6.0 |
Tritium | 2 | 0.0 |
Zidovudine/*metabolism | 2 | 33.0 |
Chromosomes, Human, Pair 17 | 3 | 0.0 |
Models, Chemical | 2 | 0.0 |
Thymidine Kinase/*genetics/metabolism | 2 | 28.0 |
Macromolecular Substances | 2 | 0.0 |
Isoenzymes/*metabolism | 3 | 1.0 |
Neoplasms/enzymology | 2 | 11.0 |
Aged, 80 and over | 4 | 0.0 |
Leukocytes/*enzymology | 2 | 3.0 |
Chromatography, Thin Layer | 2 | 1.0 |
Mutagenesis | 2 | 0.0 |
T-Lymphocytes/*drug effects/enzymology | 2 | 20.0 |
Chromatography, Affinity | 2 | 0.0 |
Adenosine Triphosphate/metabolism | 7 | 1.0 |
Cell Line, Tumor | 2 | 0.0 |
Deoxyadenine Nucleotides/chemistry/*metabolism | 2 | 66.0 |
*Deoxyribonucleases, Type II Site-Specific | 2 | 3.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Galactokinase/*genetics | 2 | 33.0 |
Lymphoma/*enzymology | 2 | 33.0 |
Cytidine Triphosphate/metabolism | 2 | 33.0 |
